Section Arrow
PBYI.NASDAQ
- Puma Biotechnology
Quotes are at least 15-min delayed:2026/06/03 21:37 EDT
Regular Hours
Last
 6.81
-0.17 (-2.44%)
Day High 
7.04 
Prev. Close
6.98 
1-M High
7.87 
Volume 
226.17K 
Bid
6.7
Ask
6.97
Day Low
6.79 
Open
6.96 
1-M Low
6.6 
Market Cap 
355.28M 
Currency 美元 
P/E 14.19 
%Yield -- 
10-SMA 7.1 
20-SMA 7.14 
50-SMA 7.13 
52-W High 7.8983 
52-W Low 3.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.48/0.83
Enterprise Value
359.99M
Balance Sheet
Book Value Per Share
2.52
Cash Flow
Cash Flow Yield
0.15
Income Statement
Total Revenue
228.37M
Operating Revenue Per Share
4.50
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ADTXAditxt Inc.0.0949-0.0149-13.57%-- 
VRAXVirax Biolabs Group Limited0.2401+0.0238+11.00%-- 
RXRXRecursion Pharmaceuticals3.47-0.14-3.88%-- 
CLDICalidi Biotherapeutics0.1656-0.0145-8.05%-- 
GOSSGossamer Bio0.1883-0.0119-5.94%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also, it is developing Alisertib, a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis, resulting in apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.